In addition, the phase-1 dose-escalation study demonstrated ARV-471 as a tolerable single agent and showed anticancer benefit in ER+/HER2 breast cancer patients who were previously on hormonal therapy or cyclin-dependent kinase (CDK)4/6 inhibitor [207]. Here, ESR1 is linked to breast cancer.